Showing Results for: “Glycemic Index and Diabetes”

Ten grants from the American Diabetes Association and the American Heart Association’s joint initiative aim to decrease heart disease and stroke among people with type 2 diabetes. The American Diabetes Association® and the American Heart Association® have awarded up to $900,000 to organizations to help people living with type 2 diabetes lower their risk for cardiovascular diseases like heart attack, heart failure and stroke. The community grants are part of the leading health non-profits’ joint Know Diabetes by Heart™ initiative which seeks to reduce cardiovascular events and deaths among

The American Diabetes Association® applauds Vermont’s governor and legislature for passing a cap on insulin co-pays. Today, Vermont House Bill 969 was signed into law by Governor Phil Scott. The law limits cost-sharing for insulin to $100 per 30-day supply for those with state-regulated commercial health insurance, a measure supported by the American Diabetes Association (ADA). The cap applies to the enrollee’s total insulin cost, so if someone requires more than one type of insulin, their cost-sharing would still not exceed $100 in total. Stephen Habbe, Director for State Government Affairs

As COVID-19 puts people with diabetes and minorities in the crosshairs, ADA calls for a Health Equity Bill of Rights to address systemic health inequities The American Diabetes Association® (ADA), the nation’s leading organization for all people living with diabetes, announced today the launch of #HealthEquityNow, a national platform to ensure that all people living with diabetes, and the millions of underserved Americans who are at greatest risk for diabetes, have access to health resources that are too often unavailable to them. The ADA calls on businesses, policymakers, philanthropies and

The American Diabetes Association® applauds Connecticut’s governor and legislature for passing a cap on co-pays for diabetes medications and supplies Recently, Connecticut House Bill 6003 was signed into law by Governor Ned Lamont. The law limits cost sharing for insulin and other diabetes medications to $25 per 30-day supply for those with state-regulated commercial health insurance. The law also caps diabetes devices and supplies at $100 per 30-day supply, allows for someone with an expired prescription to obtain insulin in an emergency, and establishes a workgroup on connecting people in

The American Diabetes Association ® applauds the Washington governor and legislature for passing SB 6087 Recently, Washington Governor Jay Inslee signed into law American Diabetes Association (ADA)-supported legislation capping monthly copayments for insulin at $100 for a 30-day supply. Senate Bill 6087 (SB 6087) requires insulin to be covered by state regulated commercial health insurance plans and state employee plans without being subject to a deductible. In addition, any cost sharing the individual is required to pay by their policy will be applied toward their deductible. The bill also

The American Diabetes Association ® applauds the Virginia governor and legislature for passing HB 66 Recently, House Bill 66 (HB 66) was signed into law by Virginia Governor Ralph Northam. This legislation, which was supported by the American Diabetes Association (ADA), will limit cost sharing to $50 per 30-day supply of insulin for those with state-regulated commercial insurance. LaShawn McIver, MD, MPH, Senior Vice President of Government Affairs & Advocacy for the ADA, issued the following statement: “Insulin has tripled in price between 2002 and 2013, forcing far too many Americans to make

The American Diabetes Association ® applauds the New York governor and legislature for passing insulin co-pay cap in state budget Recently, New York State Senate Bill 7506-B (S7506B) was signed into law by Governor Andrew Cuomo as part of the 2020 New York State Budget. A provision in the law limits cost sharing for insulin to $100 per 30-day supply for those with state-regulated commercial insurance, a measure supported by the American Diabetes Association (ADA). The new law will take effect as plans are issued or renewed in the upcoming year. LaShawn McIver, MD, MPH, Senior Vice President of

Consumers should first check with their pharmacist to see if their metformin prescription is affected The U.S. Food and Drug Administration (FDA) recently announced a recall on extended-release (ER) metformin drugs from five manufacturers due to testing results showing N-Nitrosodimethylamine (NDMA) above the acceptable intake limit in certain lots. Type 2 diabetes patients who are currently taking an ER version of metformin and are unsure if their medication is affected, should first check with their pharmacist to see if their prescribed medication is one of the five being recalled: Apotex –

“The American Diabetes Association ® (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. The ADA has led the charge to enact cost-sharing limits on insulin in 22 states and D.C., and the first-ever federal copay cap in Medicare. We are encouraged that all of the major manufacturers have taken steps to make insulin more affordable, but the fight is not over. We will continue advocating for efforts in Congress and states across the country to ensure insulin is affordable to everyone with

“The American Diabetes Association ® (ADA) applauds the long-awaited passage of Medicaid expansion in North Carolina. With more than 1 million people in North Carolina living with diagnosed diabetes, ADA believes this is a transformative step towards improving health access and health outcomes. An individual’s ability to manage diabetes is directly tied to his or her ability to access affordable and adequate health insurance coverage. States that have expanded Medicaid have seen a vast improvement in self-reported access to care and diabetes management, providing enrollees with vital access to